SUKHPREET KAUR: Open Payments
NPI 1083951735 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 23 payments from 14 companies in 2025. Trend: 2023 $415 · 2024 $640 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 4 | $153 |
| Fresenius USA Marketing, Inc. | 3 | $61 |
| Alexion Pharmaceuticals, Inc. | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Amgen Inc. | 2 | $36 |
| SCPHARMACEUTICALS INC. | 2 | $36 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| AKEBIA THERAPEUTICS INC | 1 | $27 |
| Botanix SB Inc | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $22 |
Products named: TARPEYO, VELPHORO, ULTOMIRIS, KRYSTEXXA, FUROSCIX, BENLYSTA, Vafseo, SOFDRA.
Industry payments across CA — which companies pay providers there.
